-

10:50:59 AM

VNDA Stock News

VNDA - Vanda Pharmaceuticals Inc

06/05/23 7:00 AM

Nasdaq : VNDA

Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference

Vanda Pharmaceuticals Inc. today announced that the company will participate in the Jefferies 2023 Global Healthcare Conference in New York City on Friday, June 9, 2023. A corporate presentation is scheduled for 12:15 p.m. Eastern Time. The corporate presentation given at the Jefferies 2023 Global Healthcare...

RHEA-AI

neutral

06/01/23 9:41 PM

Nasdaq : VNDA

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

Vanda Pharmaceuticals Inc. today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3– 7, 2023.. The following will be presented:. Presentation Title: "Melanopsin Genetic Variants and Delayed Sleep Phenotype– Whole Genome Sequencing Analysis" Poster Number: 94 Presenter: Dr.

RHEA-AI

neutral

06/01/23 9:31 PM

Nasdaq : VNDA

clinical trial

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Vanda Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration has granted Orphan Drug Designation for VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2 S, caused by cryptic splice site variants within IGHMBP2. CMT2S is a rare subtype of Charcot-Marie-Tooth disease, an inherited...

RHEA-AI

positive

05/25/23 7:00 AM

Nasdaq : VNDA

clinical trial

Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

Vanda Pharmaceuticals Inc. today announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. The Phase III study was conducted in real-world...

RHEA-AI

neutral

05/10/23 2:26 PM

Nasdaq : VNDA

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal

Today a three-judge panel of the United States Court of Appeals for the Federal Circuit issued a written opinion that affirmed a December 13, 2022, decision of the United Sates District Court for the District of Delaware, which held that the asserted claims of Vanda's U.S. Patent Nos. HETLIOZ ® is also approved in the European Union and is not subject to this...

RHEA-AI

neutral

05/04/23 6:00 PM

Nasdaq : VNDA

Vanda Pharmaceuticals Announces Presentations at DDW 2023

Vanda Pharmaceuticals Inc. today announced participation at Digestive Disease Week 2023, to be held in Chicago, IL and online from May 6-9, 2023.. The following will be presented:. Presentation Title: "THE ROLE OF TENASCIN-X IN IDIOPATHIC GASTROPARESIS: WGS ANALYSIS" Poster Number: Su1618 Presenter: Dr.

RHEA-AI

neutral

05/03/23 4:01 PM

Nasdaq : VNDA

earnings

Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results

Total net product sales from HETLIOZ ® and Fanapt ® were $62.5 million in the first quarter of 2023, a 4% increase compared to $60.2 million in the first quarter of 2022. HETLIOZ ® net product sales were $39.6 million in the first quarter of 2023, a 7% increase compared to $37.0 million in the first quarter of 2022. Net product sales for the first quarter of 2023...

RHEA-AI

negative

05/02/23 12:46 PM

Nasdaq : VNDA

Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information

Vanda Pharmaceuticals Inc. today announced its action against the federal government for the uncompensated taking and misuse of Vanda's trade secrets and confidential information. Vanda alleges that the U.S. Food and Drug Administration improperly provided confidential details from Vanda's drug master files for its...

RHEA-AI

neutral

04/27/23 6:00 PM

Nasdaq : VNDA

earnings

Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023

Vanda Pharmaceuticals Inc. today announced it will release results for the first quarter 2023 on Wednesday, May 3, 2023, after the market closes. A replay of the call will be available on Wednesday, May 3, 2023, beginning at 8:30 PM ET and will be accessible until Wednesday, May 10, 2023, at 8:30 PM ET. For more on Vanda Pharmaceuticals Inc., please visit...

RHEA-AI

neutral

03/28/23 1:26 PM

Nasdaq : VNDA

Vanda Prevails in Jet Lag Litigation Against the FDA

Vanda Pharmaceuticals Inc. today announced a win in its jet lag FOIA litigation against the FDA. Food and Drug Administration, case no. 1:22- cv-00938, in the United States District Court for the District of Columbia in April 2022 to compel the FDA to produce, as required by FOIA, certain records relating to its denial of Vanda's supplemental New Drug Application...

RHEA-AI

neutral

1 2 3 4 5 6 Next